TScan Therapeutics (TCRX) News Today → America could fall from this event (From Porter & Company) (Ad) Free TCRX Stock Alerts $8.01 +0.28 (+3.62%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 12:55 AM | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Apellis Pharmaceuticals (APLS), TScan Therapeutics (TCRX)May 13 at 7:55 PM | markets.businessinsider.comKey Takeaways From TScan Therapeutics Analyst RatingsMay 13 at 6:50 PM | marketbeat.comTScan Therapeutics' (TCRX) "Outperform" Rating Reaffirmed at WedbushWedbush reaffirmed an "outperform" rating and issued a $10.00 target price on shares of TScan Therapeutics in a report on Monday.May 13 at 2:33 PM | investorplace.comTCRX Stock Earnings: TScan Therapeutics Misses EPS, Misses Revenue for Q1 2024May 13 at 8:19 AM | marketbeat.comNeedham & Company LLC Reiterates Buy Rating for TScan Therapeutics (NASDAQ:TCRX)Needham & Company LLC reiterated a "buy" rating and set a $11.00 price target on shares of TScan Therapeutics in a research note on Monday.May 13 at 7:00 AM | globenewswire.comTScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for TScan Therapeutics Amid Innovative Tumor Treatment and Promising Clinical TrialsMay 9, 2024 | globenewswire.comTScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid TumorsApril 30, 2024 | marketbeat.comabrdn plc Buys Shares of 200,000 TScan Therapeutics, Inc. (NASDAQ:TCRX)abrdn plc bought a new stake in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 200,000 shares of the company's stock, valued at approximately $1,166,000. abrdn plc owned about 0.April 27, 2024 | marketbeat.comShort Interest in TScan Therapeutics, Inc. (NASDAQ:TCRX) Expands By 91.3%TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) was the recipient of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 419,700 shares, an increase of 91.3% from the March 31st total of 219,400 shares. Based on an average daily volume of 193,600 shares, the short-interest ratio is currently 2.2 days. Currently, 1.1% of the shares of the stock are sold short.April 24, 2024 | globenewswire.comTScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual MeetingApril 24, 2024 | globenewswire.comTScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional SharesApril 23, 2024 | markets.businessinsider.comUnveiling 4 Analyst Insights On TScan TherapeuticsApril 23, 2024 | marketbeat.comTScan Therapeutics' (TCRX) Outperform Rating Reaffirmed at WedbushWedbush restated an "outperform" rating and issued a $10.00 target price on shares of TScan Therapeutics in a research note on Tuesday.April 22, 2024 | globenewswire.comTScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual MeetingApril 22, 2024 | seekingalpha.comSimplify Propel Opportunities ETF: Healthcare Likely To Rise Again In FY24 And BeyondApril 19, 2024 | globenewswire.comTScan Therapeutics Announces Closing of Upsized Public OfferingApril 19, 2024 | marketbeat.comWedbush Equities Analysts Reduce Earnings Estimates for TScan Therapeutics, Inc. (NASDAQ:TCRX)TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Analysts at Wedbush lowered their Q1 2024 earnings estimates for TScan Therapeutics in a research report issued to clients and investors on Wednesday, April 17th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.27)April 18, 2024 | marketbeat.comWedbush Comments on TScan Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:TCRX)TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Equities research analysts at Wedbush issued their Q1 2025 earnings per share (EPS) estimates for shares of TScan Therapeutics in a research note issued to investors on Wednesday, April 17th. Wedbush analyst D. Nierengarten anticipates that tApril 18, 2024 | investing.comTScan launches $125 million public stock offeringApril 17, 2024 | marketbeat.comTScan Therapeutics (NASDAQ:TCRX) Stock Rating Reaffirmed by WedbushWedbush reissued an "outperform" rating and set a $10.00 target price on shares of TScan Therapeutics in a research report on Wednesday.April 17, 2024 | finanznachrichten.deTScan Therapeutics, Inc.: TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term PrioritiesApril 17, 2024 | markets.businessinsider.comTScan Therapeutics Announces Pricing Of Public Offering - Quick FactsApril 17, 2024 | finance.yahoo.comTScan Therapeutics Announces Pricing of Upsized $150 Million Public OfferingApril 16, 2024 | finance.yahoo.comTScan Therapeutics Announces Launch of $125 Million Proposed Public OfferingApril 16, 2024 | globenewswire.comTScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term PrioritiesApril 8, 2024 | markets.businessinsider.comTScan Therapeutics Appoints Chrystal Louis As Chief Medical Officer - Quick FactsApril 8, 2024 | markets.businessinsider.comTScan Therapeutics Appoints Louis As CMOApril 8, 2024 | finance.yahoo.comTScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical OfficerApril 8, 2024 | globenewswire.comTScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D.April 2, 2024 | globenewswire.comTScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 26, 2024 | finance.yahoo.comHedge funds investors control 50% of TScan Therapeutics, Inc. (NASDAQ:TCRX) and were rewarded last week after stock increased 16%March 17, 2024 | investorplace.comLow-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck WithMarch 14, 2024 | marketbeat.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Sees Significant Decrease in Short InterestTScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) was the recipient of a significant decrease in short interest in February. As of February 29th, there was short interest totalling 187,700 shares, a decrease of 25.8% from the February 14th total of 252,900 shares. Approximately 0.5% of the company's stock are sold short. Based on an average daily volume of 158,600 shares, the days-to-cover ratio is presently 1.2 days.March 11, 2024 | markets.businessinsider.comPositive Outlook for TScan Therapeutics with Promising Clinical Trials and Strong Financial PositionMarch 8, 2024 | marketbeat.comHC Wainwright Comments on TScan Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:TCRX)TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Analysts at HC Wainwright issued their FY2028 earnings per share estimates for shares of TScan Therapeutics in a note issued to investors on Thursday, March 7th. HC Wainwright analyst A. Fein forecasts that the company will post earnings of (March 7, 2024 | markets.businessinsider.comStrong Buy Rating for TScan Therapeutics Amidst Promising Drug Developments and Financial HealthMarch 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for TScan Therapeutics Following Promising Phase 1 ResultsMarch 7, 2024 | finance.yahoo.comTScan Therapeutics Inc (TCRX) Reports Increased Revenue and Expands Clinical PipelineMarch 7, 2024 | marketbeat.comTScan Therapeutics (NASDAQ:TCRX) Releases Earnings ResultsTScan Therapeutics (NASDAQ:TCRX - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.08. TScan Therapeutics had a negative net margin of 521.60% and a negative return on equity of 65.79%.March 7, 2024 | marketbeat.comHC Wainwright Reaffirms Buy Rating for TScan Therapeutics (NASDAQ:TCRX)HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of TScan Therapeutics in a research report on Thursday.March 6, 2024 | benzinga.comTScan Therapeutics: Q4 Earnings InsightsMarch 6, 2024 | investorplace.comTCRX Stock Earnings: TScan Therapeutics Beats EPS, Beats Revenue for Q4 2023March 6, 2024 | globenewswire.comTScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 28, 2024 | globenewswire.comTScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 27, 2024 | markets.businessinsider.comStrong Buy Rating for TScan Therapeutics Backed by Positive Phase 1 Trial Data and Promising Treatment EfficacyFebruary 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for TScan Therapeutics Following Promising TCR-T Therapy Trial OutcomesFebruary 26, 2024 | globenewswire.comTScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTRFebruary 21, 2024 | markets.businessinsider.comBuy Rating for TScan Therapeutics Supported by Iovance’s FDA Approval and Promising TIL Therapy BenchmarkFebruary 19, 2024 | finance.yahoo.comTScan Therapeutics, Inc. (TCRX) Stock Jumps 18.1%: Will It Continue to Soar? Get TScan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Crypto Millionaire Says: “Buy This $11 AI Coin.” (Ad)Right now, you can harness the power of two bull markets... Artificial intelligence...And cryptos. Find out more about this $11 AI Coin right now TCRX Media Mentions By Week TCRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TCRX News Sentiment▼0.130.57▲Average Medical News Sentiment TCRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TCRX Articles This Week▼112▲TCRX Articles Average Week Get TScan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Replimune Group News Today Tourmaline Bio News Today Ocugen News Today Alvotech News Today Solid Biosciences News Today Fate Therapeutics News Today Lexeo Therapeutics News Today iTeos Therapeutics News Today Black Diamond Therapeutics News Today Adaptive Biotechnologies News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TCRX) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersGuard Against the Coming Financial UpheavalPorter & CompanyElon’s New Device is About to Shock the WorldInvestorPlaceConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe only AI company you should be looking atBehind the MarketsCharles Payne Demystifies OptionsUnstoppable ProsperityForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressGold ManiaStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
